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Introduction
In normal circumstances, platelets flow uninterruptedly along the vascular endothelium without adhering or aggregating. However, upon disruption of the integrity of the vessel wall, rapid and multifaceted interactions between circulating platelets, endothelial cells and subendothelial structures occur [1] . As a result, platelets adhere to the vessel wall, are activated, and form aggregates with each other, leading to microvascular obstruction and cessation of bleeding. This interaction between platelets and the vessel wall is mediated by cellular receptors on the platelet surfaces and endothelial cells, including integrins and selectins, and by adhesive proteins, such as von Willebrand factor (VWF) and fibrinogen.
VWF is a large polymer of disulfide-linked subunits, reaching a molecular mass ranging from 500 kDa to > 10 000 kDa, which translates to coiled molecules up to 1250 nm in length (thereby equaling the size of platelets). Larger VWF multimers have much stronger hemostatic competency than smaller molecules, as they contain relatively large numbers of the sites that mediate interactions between the endothelial cells, subendothelial matrix, and platelet receptors [2] .
The size of VWF multimers is regulated by ADAMTS-13, also known as VWF-cleaving protease. ADAMTS-13 is a protease that is capable of cleaving ultralarge multimers of VWF, thereby decreasing VWF's prohemostatic properties [3] . Decreased levels of ADAMTS-13 lead to a reduced capability to degrade ultralarge VWF multimers. The ensuing increase in platelet-vessel wall interactions can lead to a thrombotic microangiopathy, clinically manifesting as a syndrome with multiple organ dysfunction, most prominently in the brain and kidneys, but potentially affecting all organs. Ongoing consumption of platelets will result in thrombocytopenia, and microvascular obstruction may cause red cell fragmentation (nonimmune hemolytic anemia) [4] .
The most typical and extreme form of thrombotic microangiopathy is thrombocytopenic thrombotic purpura (TTP), caused by an almost complete deficiency of ADAMTS-13 [5] . TTP is rare, with an annual incidence in the Western world of two per million [6] . It may be caused by a congenital deficiency in ADAMTS-13 or acquired antibodies against the protease, the latter being most common. The trigger for the formation of autoantibodies against ADAMTS-13 is incompletely understood, but is hypothesized to be a combination of genetic predisposition and acquired factors, such as infection or pregnancy [7] .
Other forms of thrombotic microangiopathy, such as hemolytic-uremic syndrome, or the thrombotic microangiopathy associated with malignant hypertension, may also be associated with lower levels of ADAMTS-13 [8] [9] [10] . However, this occurs to a more moderate extent, and, in some cases, ADAMTS-13 levels may be normal [11] .
Sepsis is another clinical condition in which thrombotic microangiopathy may occur, and this is often associated with decreased levels of ADAMTS-13 [12] . We will describe how thrombotic microangiopathy can be a component of the coagulopathy that occurs in patients with sepsis, the role and prognostic significance of ADAMTS-13 in sepsis and severe infection, and potential therapeutic implications.
Thrombotic microangiopathy in sepsis
Sepsis is now defined as a dysregulated host response to infection that results in life-threatening organ dysfunction [13] . Patients with sepsis almost always have coagulation abnormalities [14] . Hemostatic changes may range from subtle activation of coagulation that can only be detected by molecular assays for clotting factor activation, to more serious activation of coagulation that can be detected by a decrease in platelet count and slight elongation of global clotting assay times [15] . In its most excessive form, overt disseminated intravascular coagulation (DIC) may occur; this is associated with diffuse microvascular thrombosis in small and moderate-size vessels, and simultaneous widespread hemorrhage [16, 17] .
Patients with sepsis may also show signs of thrombotic microangiopathy, causing further consumption of platelets, and non-immune hemolysis. Indeed, the occurrence of schistocytes in the blood film is not uncommon in patients with sepsis. Thrombotic microangiopathy as such does not lead to excess thrombin generation and fibrin formation, and will not affect the levels of coagulation factors. However, as septic patients may present with a combination of DIC, characterized by platelet activation and fibrin generation, and thrombotic microangiopathy, it is difficult to distinguish between these mechanisms in practice.
Similarly to other types of thrombotic microangiopathy, that associated with sepsis is caused by an enhanced platelet-vessel wall interaction. A crucial factor in the pathogenesis of this enhanced platelet-vessel wall interaction is thought to be the release of (ultralarge) VWF multimers as a result of inflammation-induced endothelial cell perturbations. VWF is an acute-phase protein that is markedly upregulated and released during systemic inflammation [18] .
In addition to very high levels of VWF antigen and VWF propeptide (indicating substantial release of the protein), ultralarge VWF multimers are found in the blood of septic patients and correlate with disease severity [19] .
Apart from playing a role as a ligand between platelets and the (sub)endothelium, ultralarge VWF may also play a role in further attracting leukocytes to the injured endothelium, facilitating complement activation, and promoting adhesion of microorganisms to the surface of the vessel wall [20] . Neutrophil extracellular traps (NETs) are released in response to infection and inflammation, and have associations with disease severity and mortality [21, 22] . In TTP, NET levels are related to the platelet count and disease remission/exacerbation. Their role in local thrombosis, associated with platelet aggregation and systemic thrombosis, is well documented. In TTP, treatment with ADAMTS-13 replacement during plasma exchange is associated with a reduction in detectable levels of NETs [23] .
The level of (ultralarge) VWF multimers in patients with sepsis was inversely correlated with the plasma level of ADAMTS-13. Several studies have also confirmed the association between low ADAMTS-13 levels and sepsis severity [18, 19] . Hypothetically, the inflammationmediated massive release of VWF from the endothelium consumes and depletes the available level of ADAMTS-13, leading to insufficient cleavage capacity and control of VWF multimeric size [24] . Other factors that may contribute to the reduction in plasma activity of ADAMTS-13 in patients with sepsis are proteolytic cleavage by neutrophil elastase, thrombin, or plasmin (which are all being generated during sepsis), and inhibition of the metalloprotease by proinflammatory cytokines, such as interleukin-6 [25, 26] . Furthermore, competitive inhibition of ADAMTS-13 binding to VWF caused by high levels of thrombospondin-1 during severe inflammatory states may (theoretically) contribute to the failure to adequately regulate cleavage of ultralarge VWF multimers [27] .
Experimental studies lend support to the above-described mechanisms. In a porcine Escherichia coli sepsis model, decreased levels of ADAMTS-13 were related to increased levels of ultralarge VWF multimers in plasma, and the deposition of clots rich in VWF and platelets in kidneys, leading to tubular damage [28] . Interestingly, in VWF-deficient mice subjected to abdominal sepsis caused by cecal ligation and puncture, no reduction in ADAMTS-13 levels was observed (in contrast to a marked reduction in wildtype mice), supporting the hypothesis that the ADAMTS-13 deficiency in sepsis is attributable to consumption resulting from massive release of ultralarge VWF multimers [29, 30] . In addition, pretreatment of endotoxemic mice with inhibitors of neutrophil elastase or endotoxemic mice deficient in plasminogen attenuated the reduction in ADAMTS-13 levels, indicating that proteolytic cleavage of ADAMTS-13 during systemic inflammation may also play a role [31] .
ADAMTS-13 levels in patients with sepsis
Several studies have focused on ADAMTS-13 levels in patients with sepsis. Up to one-third of patients with sepsis have ADAMTS-13 levels that are < 50% of normal [18, 24, 32, 33] . One study reported that 15% of patients had severely reduced (< 10%) ADAMTS-13 levels; however, it should be noted that this study was performed in Japanese patients, who have a relatively high frequency of the ADAMTS-13 p.P475S polymorphism (allele frequency of 10%), which is urea-sensitive. As ADAMTS-13 levels in this study were measured with a urea-based assay, these much reduced levels may have been spuriously low [24] . Studies in septic children have also reported decreased ADAMTS-13 levels in the majority of cases, with the deficiency strongly correlating with more severe coagulopathy [34] [35] [36] . Low levels of ADAMTS-13 in sepsis are associated with reduced levels of cleaved VWF [12] . Low levels of ADAMTS-13 are also seen more frequently in patients with overt DIC, and are strongly correlated with more severe renal insufficiency [24, 37] . The decrease in ADAMTS-13 levels appears to be clearly associated with severity and increasing organ failure scores [37] . Interestingly, plasma levels of ADAMTS-13 were significantly lower (mean level of 31%) in patients with sepsis than in patients with other systemic inflammatory conditions with a non-infective etiology (mean level of 56%) [38] .
Malaria can also present with features of thrombotic microangiopathy. Malaria-infected patients have higher VWF and lower ADAMTS-13 levels. The proposed mechanism behind the decrease in ADAMTS-13 activity in malaria is endothelial activation caused by parasitized erythrocytes [39, 40] . In addition, free hemoglobin may interfere with VWF multimeric size by oxidizing the ADAMTS-13 cleavage site in VWF [41] .
One study compared ADAMTS-13 activity in patients suffering from severe or uncomplicated Plasmodium falciparum malaria in Bangladesh. In the severe malaria group (with a mortality rate of 23%), ADAMTS-13 activity was statistically reduced (mean activity of 23%) in comparison with that in the uncomplicated malaria group (mean activity of 56%) [42] . Similarly, a recent study demonstrated low levels of ADAMTS-13 in patients infected with Burkholderia pseudomallei (melioidosis), which is a common cause of severe Gram-negative infection in Asia [43] . Mean ADAMTS-13 levels in these patients were 31%, and were associated with enhanced VWF release and high levels of ultralarge VWF multimers.
Prognostic significance of ADAMTS-13
A strong association has been reported between the magnitude of the decrease in ADAMTS-13 levels in patients with sepsis and an adverse outcome. Significantly lower ADAMTS-13 levels are seen at the time of intensive care admission in eventual non-survivors [32, 35, 44] . Patients with ADAMTS-13 plasma levels of ≤50% had an approximately 10% higher risk of death than patients who presented with no or only mild reductions in ADAMTS-13 levels [34, 45] . One recent study demonstrated an approximately 50% lower survival rate in patients (mortality of 59%) with septic shock and ADAMTS-13 levels of < 30% than in patients with higher levels of ADAMTS-13 (mortality of 28%) [46] . The predictive value of ADAMTS-13 deficiency for mortality was as powerful as those of APACHE II or similar risk scores [47] .
ADAMTS-13 as a therapeutic target in sepsis
As microvascular thrombotic obstruction may be relevant in the pathogenesis of organ dysfunction in patients with sepsis, it may be suggested that targeting the platelet-vessel wall interaction in sepsis needs further exploration. In view of the central role of ultralarge VWF multimers and the function of ADAMTS-13 in regulating VWF multimeric size, this may hypothetically be an interesting point of impact for a potentially effective (adjunctive) treatment in septic patients [48] . It should be emphasized, however, that so far there is no solid evidence indicating that restoration of ADAMTS-13 and/or VWF multimeric size will result in a clinically meaningful improvement of the outcome of patients with sepsis.
Currently, the cornerstone of treatment for ADAMTS-13 deficiency in TTP is plasma exchange, which has clearly been shown to have a major benefit for survival [5] . The evidence base for plasma exchange in sepsis is, however, inconclusive [49] . Potentially, and in contrast to classical TTP, plasma administration rather than plasma exchange may be effective in sepsis, as there is no need to remove an autoantibody. However, the volume of plasma needed to sufficiently increase ADAMTS-13 levels may be a limiting factor.
Recombinant human ADAMTS-13 was tested in murine and rat models of thrombotic microangiopathy. In mice with targeted disruption of the ADAMTS-13 gene and challenged with recombinant VWF, the administration of recombinant ADAMTS-13 attenuated tubular damage, reduced the amount of myocardial injury, and reduced the number of animals with neurological symptoms [50] . Similarly, in a rat model of ADAMTS-13 inhibition by a polyclonal antibody and administration of multimeric VWF, treatment with recombinant ADAMTS-13 prevented the occurrence of thrombocytopenia and hemolytic anemia, and the formation of platelet/VWF-rich clots in brain and kidneys [51] . In addition to recombinant ADAMTS-13, gene therapy options have been explored. Recently, adenoassociated virus-mediated expression of recombinant ADAMTS-13 effectively regulated VWF multimeric size and protected ADAMTS-13 knockout mice challenged with shiga toxin against thrombocytopenia and death [52] . It remains to be established, however, whether restoration of ADAMTS-13 levels in sepsis will result in an improvement of clinically relevant outcomes.
An alternative to restoring ADAMTS-13 levels is targeting ultralarge VWF multimers. Agkisacucetin is a nonenzymatic platelet glycoprotein (GP) Ib receptor blocker derived from snake venom [53] . It effectively inhibits binding of VWF to platelets. It has shown good antithrombotic potential in phase I clinical studies, and is currently being evaluated in a randomized controlled phase II study in patients with acute coronary disease. So far, however, there is no documented experience in experimental or clinical sepsis. Alternatively, caplacuzimab is a humanized nanobody aimed at the platelet GP1b-binding site of VWF [54] . Early human studies showed potent inhibition of platelet aggregation; a phase II clinical trial in patients with TTP showed promising results, despite a small increase in hemorrhagic complications [41] . Also, this compound has not yet been evaluated in septic conditions. Finally, VWF-platelet binding can be affected by aptamers (oligonucleotides). However, aptamers have limited systemic bioavailability and very short elimination half-lives, which may hamper their clinical application [55] .
Targeting of VWF multimeric size can also be achieved with N-acetylcysteine (NAC), which is well known for its use as a mucolytic agent in lung disease. NAC reduces the disulfide bond within ultralarge VWF multimers, thereby decreasing their platelet-binding potential [56] . A possible explanation is that ultralarge VWF multimers bear a high resemblance to polymeric mucins. In vitro and in vivo experiments, using purified human VWF and injecting NAC into both ADAMTS-13-deficient and wildtype mice, demonstrated a reduction in the level of ultralarge VWF multimers. It is of note that administration of NAC resulted in significantly smaller thrombi in ADAMTS-13-deficient mice, although it did not prevent all thrombus formation. A clinical trial evaluating the potential use of NAC in TTP is ongoing (http://www.clini caltrials.gov; ClinicalTrials.gov Identifier: NCT01808521). A recent Cochrane systematic review did not, however, suggest any outcome benefit for NAC in sepsis [57] .
Conclusion
Increased platelet-vessel wall interaction, in its most extreme form manifesting as thrombotic microangiopathy, may be a relevant factor in the pathogenesis of sepsis and its related coagulopathy. Thrombotic microangiopathy in sepsis may be facilitated by ultralarge VWF multimers whose level could be increased because of (secondary) ADAMTS-13 deficiency. ADAMTS-13 deficiency strongly correlates with the severity of sepsis, and predicts an adverse outcome. Hypothetically, restoring ADAMTS-13 levels and/or reducing ultralarge VWF multimer levels may be effective as adjunctive treatment in patients with sepsis; however, there are no experimental or clinical evidence supporting this suggestion so far. Ultralarge VWF multimers and ADAMTS-13 may be potentially interesting targets for (adjunctive) treatment in patients with sepsis, aimed at either restoring ADAMTS-13 levels or blocking platelet-VWF inhibition. Eventually, randomized controlled studies in patients with sepsis evaluating laboratory markers of thrombotic microangiopathy and clinically relevant outcomes, including organ dysfunction and mortality, are required to establish a role of the restoration of ADAMTS-13 function in patients with sepsis.
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